Goldman Sachs downgraded Fosun to Neutral from Buy with a HK$5 price target. The analyst sees slower earnings growth for the core businesses Yuyuan, Fosun Tourism Group and Fosun Pharma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
